Compare · Head-to-head
Retatrutide vs Tirzepatide.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Tirzepatide, then use the table to confirm fit.
Tirzepatide is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Retatrutide
Investigational triple-agonist obesity drug candidate with early human weight-loss data but no approval.
01 · At a glance
| Decision factor | Retatrutide | Tirzepatide |
|---|---|---|
| Primary fit | fat loss & metabolism research where you want a clear starting point | fat loss & metabolism research where you want a clear starting point |
| Evidence | Tier C | Tier A |
| Risk | med-high | medium |
| Experience level | advanced | intermediate |
| Budget tier | premium | premium |
| Administration route | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | Retatrutide | Tirzepatide |
|---|---|---|
| Goal fit | Fat Loss & Metabolism | Fat Loss & Metabolism |
| What users compare it for | Preliminary human data suggest strong body-weight reduction and metabolic benefit, but the evidence base remains early-stage. | Large reductions in HbA1c and body weight in approved-use populations, with reduced appetite and improved metabolic markers. |
| Onset timeline | Expected to follow other incretin agents, with early appetite effects and larger changes over months. | Metabolic effects begin within weeks; major body-composition changes accrue over months. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Retatrutide | Tirzepatide |
|---|---|---|
| Adverse effects | Likely significant GI intolerance profile with limited long-term safety clarity. Broader risk remains uncertain due to limited human exposure. | GI intolerance is most common: nausea, vomiting, diarrhea, constipation, and appetite suppression. Gallbladder and pancreatitis concerns remain relevant. |
| Contraindications | Experimental compound; avoid outside regulated research or clinician-supervised contexts. | Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history, pregnancy, and other glucose-lowering drugs. |
| Interaction notes | Assume class-like overlap with GLP-1 and GIP therapies; avoid layering with other incretin agents. | Additive hypoglycemia risk with insulin or secretagogues. Delayed gastric emptying can affect oral-drug absorption timing. |
| Regulatory status | Investigational | Prescription-approved |
| FDA flag | FDA compounding caution | FDA compounding caution |
| WADA status | Status unclear | Not listed |
04 · Age & monitoring
| Decision factor | Retatrutide | Tirzepatide |
|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54, 55-64, 65+ |
| Life-stage note | Not yet documented | Most relevant in adult metabolic-health and obesity contexts rather than early-life performance use. |
| Monitoring burden | Not specified | medium |
| Follow-up cadence | Not yet documented | Early tolerance review, then periodic metabolic follow-up every few months. |
05 · Cost & sourcing
| Decision factor | Retatrutide | Tirzepatide |
|---|---|---|
| Typical cycle cost | $150.00 | $200.00 |
| Estimated monthly cost | $150.00 | $200.00 |
| Cost confidence | High confidence | Moderate confidence |
06 · Before you buy
| Decision factor | Retatrutide | Tirzepatide |
|---|---|---|
| Tracked vendor listings | 2 listings | 1 listing |
| Sourcing note | Tracked product pages exist, but naming differences mean the listing needs an extra read before purchase. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.